FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2569592316> ?p ?o ?g. }

• W2569592316 abstract "Abstract Abstract 2034 Background: Mantle cell lymphoma (MCL) is aggressive B-cell neoplasm diagnosed predominantly among elderly men. (R)CHOP-like schemes are effective in remission induction, but the progression-free survival is disappointingly short (median 16–20 months) with median overall survival of 3–4 years. Upfront use of high-dose cytarabine (12 g/m2), autoSCT and rituximab at all stages of therapy is the most effective treatment but possible only with patients younger 65 years. Decrease in AraC doses to 4 g/m2 per cycle significantly reduce progression free survival. Prominent efficacy of gemcitabine-oxaliplatin combinations and irinotecan in relapsed and refractory MCL patients allowed including these drugs in first-line treatment in cases when the scheme R-HD-Met-AraC (Romanguera J. 2005) is impossible. Aim: Toxicity and efficacy assessment of schemes R-DA-EPOCH/R-GIDIOX and R-DA-EPOCH/ R-HD-Met-AraC in primary MCL patients eligible for autoSCT. Patients and Methods: Since May 2008 35 untreated MCL patients (median 55 years (29–63), males/females 68,5%/31,5%, MIPIb: 34% low, 26% intermediate, 40% high risk) were enrolled. After first R-EPOCH course (Wilson W. 2003) patients were stratified according to toxicity they had received either R-DA-EPOCH/R-HD-Met-AraC or R-DA-EPOCH/R-GIDIOX. In the absence of hematological toxicity grade 4 for more than 3 days, severe infection complications and signs of renal failure patients underwent treatment under the scheme R-HD-Met-AraC (rituximab 375 mg/m2 day 0, methotrexate 1000 mg/m2 24 hours CI day 1, cytarabine 3000 mg/m2 q 12 hrs days 2–3). If there was one of these complications patients underwent treatment under the scheme R-GIDIOX (rituximab 375 mg/m2 day 0, gemcitabine 800 mg/m2 days 1 and 4, oxaliplatin 120 mg/m2 day 2, irinotecan 100 mg/m2 day 3, dexamethasone 10 mg/m2 IV days 1–5, ifosfamide 1000 mg/m2 days 1–5). Further these courses are rotated: either R-DA-EPOCH/R-HD-Met-AraC or R-DA-EPOCH/R-GIDIOX. Depending on the terms of response, patients received 6–8 courses (3–4 cycles) of chemotherapy and autoSCT (BEAM-R) with in vivo purging by rituximab before harvest and reinfusion. Patients with residual tumor after autoSCT were consolidated with local radiotherapy. Rituximab maintenance was performed every three months for 3 years. The protocol was approved by the local ethics committee. Patients were analyzed in an intent-to-treat basis. Overall survival (OS) and event-free survival (EFS) rates were estimated (± standard error) by using the Kaplan-Meier method. Efficacy of the therapy was assessed by Cheson's response criteria (2008). Toxicity assessment was performed 93 R-DA-EPOCH, 60 R-HD-Met-AraC and 46 R-GIDIOX courses. Results: A median follow-up is 23 months (range 3–54). Toward August 2012 26 patients underwent autoSCT: 14 from R-HD-Met-AraC arm and 12 from R-GIDIOX arm. 1 induction death after first HD-Met-AraC course (acute renal failure and septic shock). Maintenance therapy with rituximab was completed in three patients. All patients achieved CR in R-HD-Met-AraC arm. In R-GIDIOX arm OR was 100%: 11 CR and 1 PR (without progression for 26 months after autoSCT). Main non-hematological toxicity of R-GIDIOX was hepatic, with elevated aminotransferases grades 1–2 and 3–4 in 59,5% and 7,1% of courses respectively, without clinical signs. The sources of stem cells were PB in 23 patients and BM in 3 cases of harvest failure after R-GIDIOX. Hematological toxicity of R-GIDIOX course: leukopenia grade 4 was in 71,4% (medium duration was 5,4 days, range 1–13), thrombocytopenia grade 4 was in 42,9%. The estimated 4-years OS rates for the R-GIDIOX group and the R-HD-Met-AraC group were 100% and 68% ± 17%. The estimated 4-years EFS rates for the R-GIDIOX group and the R-HD-Met-AraC group were 90% ± 10% and 69% ± 14%. Conclusions: Our main goal was to incorporate intensive induction, autoSCT and rituximab maintenance in first line therapy MCL patients. However, HD-Met-AraC scheme is highly toxic and its use is possible only in 2/3 of patients younger 65 years. R-GIDIOX scheme is less toxic than R-HD-Met-AraC and equally effective in response induction and mobilizing, so it could be recommended for those in whom high-dose AraC and methotrexate can potentially cause severe adverse consequences. Such an integrated approach might lead to a shift of paradigm of MCL from an incurable to a curable lymphoma. Disclosures: No relevant conflicts of interest to declare." @default.
• W2569592316 created "2017-01-13" @default.
• W2569592316 creator A5006140546 @default.
• W2569592316 creator A5015768274 @default.
• W2569592316 creator A5018133581 @default.
• W2569592316 creator A5040499157 @default.
• W2569592316 creator A5044515850 @default.
• W2569592316 creator A5051215767 @default.
• W2569592316 creator A5064127740 @default.
• W2569592316 creator A5069763928 @default.
• W2569592316 creator A5071839937 @default.
• W2569592316 creator A5077089081 @default.
• W2569592316 creator A5084122693 @default.
• W2569592316 date "2012-11-16" @default.
• W2569592316 modified "2023-09-30" @default.
• W2569592316 title "Intensive Induction, Autologous Stem Cell Transplantation and Rituximab Maintenance Has Changed Event Free Survival and Overall Survival in Mantle Cell Lymphoma Patients. Using Gemcitabine and Oxaliplatin in First Line Therapy" @default.
• W2569592316 doi "https://doi.org/10.1182/blood.v120.21.2034.2034" @default.
• W2569592316 hasPublicationYear "2012" @default.
• W2569592316 type Work @default.
• W2569592316 sameAs 2569592316 @default.
• W2569592316 citedByCount "1" @default.
• W2569592316 countsByYear W25695923162016 @default.
• W2569592316 crossrefType "journal-article" @default.
• W2569592316 hasAuthorship W2569592316A5006140546 @default.
• W2569592316 hasAuthorship W2569592316A5015768274 @default.
• W2569592316 hasAuthorship W2569592316A5018133581 @default.
• W2569592316 hasAuthorship W2569592316A5040499157 @default.
• W2569592316 hasAuthorship W2569592316A5044515850 @default.
• W2569592316 hasAuthorship W2569592316A5051215767 @default.
• W2569592316 hasAuthorship W2569592316A5064127740 @default.
• W2569592316 hasAuthorship W2569592316A5069763928 @default.
• W2569592316 hasAuthorship W2569592316A5071839937 @default.
• W2569592316 hasAuthorship W2569592316A5077089081 @default.
• W2569592316 hasAuthorship W2569592316A5084122693 @default.
• W2569592316 hasConcept C121332964 @default.
• W2569592316 hasConcept C121608353 @default.
• W2569592316 hasConcept C126322002 @default.
• W2569592316 hasConcept C1276947 @default.
• W2569592316 hasConcept C141071460 @default.
• W2569592316 hasConcept C143998085 @default.
• W2569592316 hasConcept C150846664 @default.
• W2569592316 hasConcept C2776694085 @default.
• W2569592316 hasConcept C2777525834 @default.
• W2569592316 hasConcept C2778041864 @default.
• W2569592316 hasConcept C2779050716 @default.
• W2569592316 hasConcept C2779338263 @default.
• W2569592316 hasConcept C2780258809 @default.
• W2569592316 hasConcept C2780259306 @default.
• W2569592316 hasConcept C2780317896 @default.
• W2569592316 hasConcept C2780653079 @default.
• W2569592316 hasConcept C2780962732 @default.
• W2569592316 hasConcept C2911091166 @default.
• W2569592316 hasConcept C526805850 @default.
• W2569592316 hasConcept C71924100 @default.
• W2569592316 hasConcept C90924648 @default.
• W2569592316 hasConceptScore W2569592316C121332964 @default.
• W2569592316 hasConceptScore W2569592316C121608353 @default.
• W2569592316 hasConceptScore W2569592316C126322002 @default.
• W2569592316 hasConceptScore W2569592316C1276947 @default.
• W2569592316 hasConceptScore W2569592316C141071460 @default.
• W2569592316 hasConceptScore W2569592316C143998085 @default.
• W2569592316 hasConceptScore W2569592316C150846664 @default.
• W2569592316 hasConceptScore W2569592316C2776694085 @default.
• W2569592316 hasConceptScore W2569592316C2777525834 @default.
• W2569592316 hasConceptScore W2569592316C2778041864 @default.
• W2569592316 hasConceptScore W2569592316C2779050716 @default.
• W2569592316 hasConceptScore W2569592316C2779338263 @default.
• W2569592316 hasConceptScore W2569592316C2780258809 @default.
• W2569592316 hasConceptScore W2569592316C2780259306 @default.
• W2569592316 hasConceptScore W2569592316C2780317896 @default.
• W2569592316 hasConceptScore W2569592316C2780653079 @default.
• W2569592316 hasConceptScore W2569592316C2780962732 @default.
• W2569592316 hasConceptScore W2569592316C2911091166 @default.
• W2569592316 hasConceptScore W2569592316C526805850 @default.
• W2569592316 hasConceptScore W2569592316C71924100 @default.
• W2569592316 hasConceptScore W2569592316C90924648 @default.
• W2569592316 hasLocation W25695923161 @default.
• W2569592316 hasOpenAccess W2569592316 @default.
• W2569592316 hasPrimaryLocation W25695923161 @default.
• W2569592316 hasRelatedWork W2462168748 @default.
• W2569592316 hasRelatedWork W2497788249 @default.
• W2569592316 hasRelatedWork W2550573620 @default.
• W2569592316 hasRelatedWork W2551854527 @default.
• W2569592316 hasRelatedWork W2552559161 @default.
• W2569592316 hasRelatedWork W2553893707 @default.
• W2569592316 hasRelatedWork W2555224139 @default.
• W2569592316 hasRelatedWork W2561487623 @default.
• W2569592316 hasRelatedWork W2561654297 @default.
• W2569592316 hasRelatedWork W2562268161 @default.
• W2569592316 hasRelatedWork W2565741037 @default.
• W2569592316 hasRelatedWork W2573473873 @default.
• W2569592316 hasRelatedWork W2581148294 @default.
• W2569592316 hasRelatedWork W2584735035 @default.
• W2569592316 hasRelatedWork W2587812940 @default.
• W2569592316 hasRelatedWork W2592106861 @default.
• W2569592316 hasRelatedWork W2965534143 @default.
• W2569592316 hasRelatedWork W2979483773 @default.
• W2569592316 hasRelatedWork W2992564836 @default.
• W2569592316 hasRelatedWork W3210051517 @default.
• W2569592316 isParatext "false" @default.

• next